DANNCE.AI

About DANNCE.AI

dannce.ai is focused on accelerating neurological drug development and enhancing patient care through an AI-powered digital phenotyping platform. The platform provides objective behavioral quantification using advanced motion analysis to improve clinical decision-making and optimize neurological care for clinicians and drug developers.

Products & Services

Digital Phenotyping Platform:An AI-driven platform for clinicians and drug developers to objectively measure neurological conditions through motion analysis, improving clinical decision-making, scaling patient assessments, detecting subtle drug effects, and increasing trial sensitivity.

Specialties

AI-driven motion analysis Digital phenotyping Neurological drug development Precision neurology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Pre-Seed T: - FT: Pre-Seed	A: 2600000 MR: - FA: 2.6 million FAN: 2600000	D: 2024-11-21 FD: 2024-11-21	5 investors

Pre-Seed Latest

2024-11-21

$2.6M

5 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Rob Baldoni

CEO and Co-Founder

LinkedIn (Pro only)

D

Dr. Timothy Dunn

CSO and Co-Founder

T

Timothy Dunn

Assistant Professor of Biomedical Engineering

D

Dr. Jesse Marshall

Co-Founder

S

Shereen Shermak

COO

J

Joe Chan

CTO

View 9 more team members with Pro

Unlock Full Team Directory

Recent News

DANNCE.AI Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised